# Case Scenario 1: Thyroid

#### **History and Physical**

Patient is an otherwise healthy 80 year old female with the complaint of a neck mass first noticed two weeks ago. The mass has increased in size and is palpable. Ultrasound of the thyroid and lateral neck showed a large mass of the left thyroid, but no right or left neck lymphadenopathy. Chest x-ray identified no abnormalities in left or right lung and no lymphadenopathy. Fine needle aspiration (FNA) of neck mass was performed and diagnosed carcinoma. Patient will be admitted for total thyroidectomy.

#### **Operative Report**

Operation: Total thyroidectomy

Findings: Left thyroid lobe consisting of an ovoid pink-purple rubbery mass. The mass is lobulated and extends to the capsular surface. No residual disease is present. Right thyroid lobe is smaller and normal in appearance.

#### **Pathology Report**

Gross: The specimen is labeled left thyroid lobe and consists of an  $8.0 \times 6.5 \times 4.5$  cm mass weighing 135 grams. Cut section reveals tan-white, firm, fibrotic tissue that completely replaces any normal thyroid tissue. The right thyroid lobe is  $4.0 \times 4.8 \times 1.0$  cm and weighs 30 grams. Also received was a  $2.5 \times 2.0 \times 0.5$  cm portion of lobulated adipose tissue labeled para laryngeal lymph nodes. On dissection, it contained three rubbery tan lymph nodes, measuring 1.2 cm, 1.0 cm, and 0.5 , in greatest dimension, respectively.

Final diagnosis: Left thyroid lobe with papillary carcinoma, 8 cm in size. There is extensive vascular invasion and focal extension into perithyroidal soft tissue. The right lobe is positive for multifocal follicular thyroid carcinoma. The largest foci measures 0.8 cm. One of the three lymph nodes submitted was positive for papillary carcinoma.

#### **Oncology Notes**

Patient with an 8 cm papillary carcinoma of the left thyroid was treated with a total thyroidectomy and excision of three central compartment lymph nodes. Post-operative lab tests indicated an elevated thyroglubin level (1.8 ng/mL). Basal calcitonin was undetectable and CEA level was within normal range. The patient went on to have adjuvant radioiodine <sup>131</sup>I treatment. Subsequent imaging did not show any uptake. The patient is currently taking levothyroxine as a TSH suppressant. She will have neck ultrasound as well as serum calcitonin and CEA tests in 6 months.

- How many primaries are present in case scenario 1?
- How would we code the histology of the primary you are currently abstracting?

# Stage/ Prognostic Factors

(Print two copies of this page if patient has multiple primaries)

CS Tumor Size   CS SSF 9     CS Extension   CS SSF 10     CS Tumor Size/Ext Eval   CS SSF 11     CS Lymph Nodes   CS SSF 12     CS Lymph Nodes Eval   CS SSF 13     Regional Nodes Positive   CS SSF 14     Regional Nodes Examined   CS SSF 15     CS Mets at Dx   CS SSF 16     CS Mets Eval   CS SSF 17     CS SSF 1   CS SSF 18     CS SSF 2   CS SSF 19     CS SSF 3   CS SSF 20     CS SSF 4   CS SSF 21     CS SSF 5   CS SSF 22     CS SSF 6   CS SSF 23     CS SSF 7   CS SSF 24     CS SSF 25   CS SSF 25	*	 1 1 1	
CS Tumor Size/Ext Eval   CS SSF 11     CS Lymph Nodes   CS SSF 12     CS Lymph Nodes Eval   CS SSF 13     Regional Nodes Positive   CS SSF 14     Regional Nodes Examined   CS SSF 15     CS Mets at Dx   CS SSF 16     CS Mets Eval   CS SSF 17     CS SSF 1   CS SSF 18     CS SSF 2   CS SSF 19     CS SSF 3   CS SSF 20     CS SSF 4   CS SSF 21     CS SSF 5   CS SSF 22     CS SSF 2   CS SSF 22     CS SSF 2   CS SSF 22     CS SSF 2   CS SSF 24	CS Tumor Size	CS SSF 9	
CS Lymph Nodes   CS SSF 12     CS Lymph Nodes Eval   CS SSF 13     Regional Nodes Positive   CS SSF 14     Regional Nodes Examined   CS SSF 15     CS Mets at Dx   CS SSF 16     CS Mets Eval   CS SSF 17     CS SSF 1   CS SSF 18     CS SSF 2   CS SSF 19     CS SSF 3   CS SSF 20     CS SSF 4   CS SSF 21     CS SSF 5   CS SSF 22     CS SSF 20   CS SSF 22     CS SSF 5   CS SSF 22     CS SSF 22   CS SSF 24	CS Extension	CS SSF 10	
CS Lymph Nodes Eval   CS SSF 13     Regional Nodes Positive   CS SSF 14     Regional Nodes Examined   CS SSF 15     CS Mets at Dx   CS SSF 16     CS Mets Eval   CS SSF 17     CS SSF 1   CS SSF 18     CS SSF 2   CS SSF 19     CS SSF 3   CS SSF 20     CS SSF 4   CS SSF 21     CS SSF 5   CS SSF 22     CS SSF 23   CS SSF 24     CS SSF 26   CS SSF 27     CS SSF 27   CS SSF 24	CS Tumor Size/Ext Eval	CS SSF 11	
Regional Nodes Positive   CS SSF 14     Regional Nodes Examined   CS SSF 15     CS Mets at Dx   CS SSF 16     CS Mets Eval   CS SSF 17     CS SSF 1   CS SSF 18     CS SSF 2   CS SSF 19     CS SSF 3   CS SSF 20     CS SSF 4   CS SSF 21     CS SSF 5   CS SSF 22     CS SSF 23   CS SSF 23     CS SSF 24   CS SSF 24	CS Lymph Nodes	CS SSF 12	
Regional Nodes Examined   CS SSF 15     CS Mets at Dx   CS SSF 16     CS Mets Eval   CS SSF 17     CS SSF 1   CS SSF 18     CS SSF 2   CS SSF 19     CS SSF 3   CS SSF 20     CS SSF 4   CS SSF 21     CS SSF 5   CS SSF 22     CS SSF 20   CS SSF 21     CS SSF 5   CS SSF 22     CS SSF 23   CS SSF 24	CS Lymph Nodes Eval	CS SSF 13	
CS Mets at Dx   CS SSF 16     CS Mets Eval   CS SSF 17     CS SSF 1   CS SSF 18     CS SSF 2   CS SSF 19     CS SSF 3   CS SSF 20     CS SSF 4   CS SSF 21     CS SSF 5   CS SSF 22     CS SSF 23   CS SSF 23     CS SSF 6   CS SSF 23     CS SSF 24   CS SSF 24	Regional Nodes Positive	CS SSF 14	
CS Mets Eval   CS SSF 17     CS SSF 1   CS SSF 18     CS SSF 2   CS SSF 19     CS SSF 3   CS SSF 20     CS SSF 4   CS SSF 21     CS SSF 5   CS SSF 22     CS SSF 6   CS SSF 23     CS SSF 7   CS SSF 24	Regional Nodes Examined	CS SSF 15	
CS SSF 1 CS SSF 18   CS SSF 2 CS SSF 19   CS SSF 3 CS SSF 20   CS SSF 4 CS SSF 21   CS SSF 5 CS SSF 22   CS SSF 6 CS SSF 23   CS SSF 7 CS SSF 24	CS Mets at Dx	CS SSF 16	
CS SSF 2 CS SSF 19   CS SSF 3 CS SSF 20   CS SSF 4 CS SSF 21   CS SSF 5 CS SSF 22   CS SSF 6 CS SSF 23   CS SSF 7 CS SSF 24	CS Mets Eval	CS SSF 17	
CS SSF 3   CS SSF 20     CS SSF 4   CS SSF 21     CS SSF 5   CS SSF 22     CS SSF 6   CS SSF 23     CS SSF 7   CS SSF 24	CS SSF 1	CS SSF 18	
CS SSF 4 CS SSF 21   CS SSF 5 CS SSF 22   CS SSF 6 CS SSF 23   CS SSF 7 CS SSF 24	CS SSF 2	CS SSF 19	
CS SSF 5   CS SSF 22     CS SSF 6   CS SSF 23     CS SSF 7   CS SSF 24	CS SSF 3	CS SSF 20	
CS SSF 6   CS SSF 23     CS SSF 7   CS SSF 24	CS SSF 4	CS SSF 21	
CS SSF 7 CS SSF 24	CS SSF 5	CS SSF 22	
	CS SSF 6	CS SSF 23	
CS SSF 8 CS SSF 25	CS SSF 7	CS SSF 24	
	CS SSF 8	CS SSF 25	

## **Treatment**

Diagnostic Staging Procedure		
Surgery Codes	Radiation Codes	
Surgical Procedure of Primary Site	Radiation Treatment Volume	
Scope of Regional Lymph Node	Regional Treatment Modality	
Surgery		
Surgical Procedure/ Other Site	Regional Dose	
	Boost Treatment Modality	
Systemic Therapy Codes	Boost Dose	
Chemotherapy	Number of Treatments to Volume	
Hormone Therapy	Reason No Radiation	
Immunotherapy		
Hematologic Transplant/Endocrine		
Procedure		

# Case Scenario 2: Thyroid

#### **History and Physical**

The patient is a 66 year old gentleman who presented with a left thyroid mass. The patient was evaluated at an outside facility. Fine needle aspiration was positive for carcinoma. The patient had a palpable prominent left thyroid area mass but also had prominent lymphadenopathy. The patient underwent MRI scan which revealed a large thyroid mass. In addition, there was a large zone II mass compressing the internal jugular vein. There also appeared to be lymphadenopathy in the jugular chain in zones III and IV.

#### **Operative findings**

Operation: Left thyroidectomy with ipsilateral modified neck dissection

## **Pathology**

Gross: The specimen consisted of left thyroid weighing 42.34 grams and measuring  $6.1 \times 5.2 \times 2.0$  cm. The external surface appears shiny with attached perithyroidal fat. There is no evidence of gross extension of tumor to the thyroid capsule. On cut section, there is a 4.5 cm poorly circumscribed indurated lesion with infiltrating borders and foci of hemorrhage and necrosis. The rest of the thyroid is orange-yellow, fleshy with no evidence of nodules noted.

Microscopic: The tumor includes the histological features of medullary carcinoma, which include nests or chords of cells penetrating dense pink stroma with a lobular, trabecular or even solid growth pattern. The tumor can be seen to abut normal thyroid microscopically. There is focal staining of the stroma with Congo red. There is moderate cytoplasmic staining for Calcitonin. Staining for CEA is intensely positive in all tumor cells.

Final diagnosis: Moderately differentiated medullary carcinoma of the thyroid gland, 4.5 cm, with extension to capsular margins of resection. Focal angiolymphatic invasion was identified with four of 20 level III and level IV lymph nodes positive for metastasis.

#### **Oncology Consult**

Because of the abnormal CEA and elevated calcitonin, MRI of neck, chest and abdomen were performed post-operatively. All imaging was normal. Serum calcitonin and CEA levels will be tested again in 6 months.

- How many primaries are present in case scenario 1?
- How would we code the histology of the primary you are currently abstracting?

	Sta	age/ Prog	gnostic Factors		
CS Tumor Size			CS SSF 9		
CS Extension			CS SSF 10		
CS Tumor Size/Ext Eval			CS SSF 11		
CS Lymph Nodes			CS SSF 12		
CS Lymph Nodes Eval			CS SSF 13		
Regional Nodes Positive			CS SSF 14		
Regional Nodes Examined			CS SSF 15		
CS Mets at Dx			CS SSF 16		
CS Mets Eval			CS SSF 17		
CS SSF 1			CS SSF 18		
CS SSF 2			CS SSF 19		
CS SSF 3			CS SSF 20		
CS SSF 4			CS SSF 21		
CS SSF 5			CS SSF 22		
CS SSF 6			CS SSF 23		
CS SSF 7			CS SSF 24		
CS SSF 8			CS SSF 25		
Treatment					
Diagnostic Staging Procedure					
Surgery Codes			Radiation Codes		
Surgical Procedure of Primary Site			Radiation Treatment Volume		
Scope of Regional Lymph Node			Regional Treatment Modality		
Surgery					
Surgical Procedure/ Other Site			Regional Dose		
			Boost Treatment Modality		
Systemic Therapy Codes			Boost Dose		
Chemotherapy			Number of Treatments to Volume		
Hormone Therapy			Reason No Radiation		
Immunotherapy					
Hematologic Transplant/Endocrine					
Procedure					

#### Case Scenario 3: Adrenal Gland

## History and physical

This 27 year-old white man had an unremarkable medical history until 6 months prior to admission when he was found to have hypertension which was unresponsive to medical therapy. Three weeks prior to admission he developed bilateral gynecomastia and more recently, he began experiencing very severe right flank pain while on the job. Sonogram and Computerized Tomography revealed an adrenal mass which also appeared to extend into the inferior vena cava at the level of the right adrenal gland just below the hepatic vein. No enlarged lymph nodes or other abnormalities were identified. Resection was performed.

#### **Pathology**

Gross: The resected specimen consisted of the right adrenal gland and right kidney. A 10 cm tumor was found in the adrenal gland which weighed 250 grams. The vast majority of the adrenal gland was replaced by the neoplasm which appeared to be confined within the adrenal capsule. No invasion into the adjacent kidney was seen.

Microscopic: The resected neoplasm was confined to the adrenal gland. At the edges, infiltration through the capsule of the adrenal gland was noted. The neoplasm consisted of sheets of polygonal cells with a rich vascular stroma and areas of geographic necrosis. Cytologically, the vast majority of the cells were polygonal with eosinophilic cytoplasm, a moderate degree of nuclear pleomorphism, prominent nucleoli, and vesicular chromatin pattern. In the most active areas, 35 mitoses were counted in 10 high powered fields. Invasion into the adrenal vein seen grossly was confirmed histologically. In an attempt to confirm the adrenal cortical origin of this neoplasm, a battery of immunohistochemical stains was performed. Intense staining for Synaptophysin was appreciated. Vimentin stain was also positive. Immunohistochemical stains for AE1/AE3 (cytokeratin), CAM 5.2, Epithelial Membrane Antigen, and Chromogranin were negative.

Final diagnosis: Moderately differentiated adrenal cortical carcinoma with adrenal vein invasion (10 cm, 250 gm)

## **Oncology consult**

The patient with adrenocortical carcinoma with adrenal vein invasion recently completed his final round of Mitotane. The patient is currently asymptomatic. Follow-up exam is scheduled in three months.

- How many primaries are present in case scenario 1?
- How would we code the histology of the primary you are currently abstracting?

Stage/ Prognostic Factors						
(Print two copies of this page if patient has multiple primaries)						
CS Tumor Size			CS SSF 9			
CS Extension			CS SSF 10			
CS Tumor Size/Ext Eval			CS SSF 11			
CS Lymph Nodes			CS SSF 12			
CS Lymph Nodes Eval			CS SSF 13			
Regional Nodes Positive			CS SSF 14			
Regional Nodes Examined			CS SSF 15			
CS Mets at Dx			CS SSF 16			
CS Mets Eval			CS SSF 17			
CS SSF 1			CS SSF 18			
CS SSF 2			CS SSF 19			
CS SSF 3			CS SSF 20			
CS SSF 4			CS SSF 21			
CS SSF 5			CS SSF 22			
CS SSF 6			CS SSF 23			
CS SSF 7			CS SSF 24			
CS SSF 8			CS SSF 25			
		Trea	atment			
Diagnostic Staging Procedure						
Surgery Codes			Radiation Codes			
Surgical Procedure of Primary Site			Radiation Treatment Volume			
Scope of Regional Lymph Node			Radiation Treatment Modality			
Surgery						
Surgical Procedure/ Other Site			Regional Dose			
			Boost Treatment Modality			
Systemic Therapy Codes			Boost Dose			
Chemotherapy			Number of Treatments to Volume			
Hormone Therapy			Reason No Radiation			
Immunotherapy						
Hematologic Transplant/Endocrir	ne					
Procedure						